Triglide Generic Name & Formulations
Fenofibrate 160mg; tabs.
Adjunct to diet in severe hypertriglyceridemia, to reduce elevated total-C, LDL-C, apo B, TG, and to increase HDL-C in primary hypercholesterolemia or mixed dyslipidemia.
Limitations of Use
Not shown to reduce coronary heart disease morbidity and mortality in 2 controlled trials of patients with type 2 diabetes mellitus.
Triglide Dosage and Administration
Swallow whole. 160mg once daily. Discontinue if inadequate response after 2 months.
Severe renal impairment (including dialysis). Active liver disease. Unexplained persistent liver function abnormalities. Primary biliary cirrhosis. Gallbladder disease. Nursing mothers.
Triglide Boxed Warnings
Risk of serious liver injury. Monitor liver function at baseline and periodically during therapy; discontinue if liver injury develops or if elevated enzymes persist (ALT or AST >3×ULN, or if accompanied by elevated bilirubin); do not restart if no alternative explanation. Monitor CBCs during the first year. Discontinue if markedly elevated CPK levels, myopathy, gallstones, hypersensitivity reactions, or paradoxical decreases in HDL occur (do not reinitiate). Diabetes. Hypothyroidism. Mild to moderate renal impairment: avoid. Elderly. Pregnancy (Cat.C).
Avoid statins. Potentiates oral anticoagulants (reduce anticoagulant dose and monitor PT/INR); caution. Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with colchicine, immunosuppressants (eg, cyclosporine, tacrolimus), other nephrotoxic drugs.
Triglide Adverse Reactions
Abnormal liver function tests, increased AST, ALT, CPK, rhinitis; respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased serum creatinine, rash, hypersensitivity reactions (may be severe); rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Triglide Clinical Trials
Triglide Patient Counseling